For over 50 years, the Bioanalysis and Pharmacokinetics Lab has provided drug analysis to research communities of the University of Washington and Fred Hutchinson Cancer Research Center. The PK Lab has also collaborated with other institutions including Bastyr University, The Geneva Foundation, Oregon Health Sciences University, Seattle Children’s Hospital, St. Jude Children’s Research Hospital, and the University of Texas Southwest Medical Center.
At the present, the lab supports clinical studies through the analysis of drugs in an array of biological matrices (e.g. plasma, urine, lymphocytes), along with analysis and modeling of pharmacokinetic-pharmacodynamic (PK-PD) data. The PK Lab also has the capability to conduct various studies for the in vitro characterization of drug metabolism and transport.
In addition to small molecule bioanalysis, the lab supports targeted and untargeted proteomics projects.
Description of services:
The Pharmacokinetics Laboratory can support both preclinical and clinical research protocols through the development and utilization of bioanalytical methods. Our core services, represented below, can be adapted to a variety of investigational objectives:
- Research project development and grant development
- Consultation and presentation of data
- Development and validation (according to FDA guidelines) of bioanalytical methods
- Routine, high-throughput analysis of drug metabolites at low concentrations in complex biological matrices
- Serum, plasma, whole blood, urine, lymphocytes, cerebrospinal fluid, and brain / spinal cord
- Pharmacokinetic modeling, ranging from noncompartmental analysis to full population pharmacokinetic analysis
- In vitro metabolic studies with tissue subcellular fractions and recombinant enzymes to characterize metabolite formation kinetics, identify drug-metabolizing enzymes, and drug-drug interactions
- Pharmacogenomics studies involving genotype-phenotype correlations
- PK-PD correlation studies with validated biomarkers